#45 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
Clinicians in North Carolina should understand that the $3.2 billion annual illicit market represents patients obtaining cannabis without quality controls, potency labeling, or contamination screening, which directly impacts their ability to counsel patients on safe dosing and drug interactions. Legalization could shift patients from unregulated to regulated products with standardized testing and medical oversight, allowing clinicians to provide evidence-based guidance on cannabis use similar to other states with legal frameworks. This policy shift matters because clinicians currently cannot reliably assess what their patients are consuming or recommend safer alternatives within a legal structure.
North Carolina’s advisory council has recommended marijuana legalization based on evidence that residents spent an estimated 3.2 billion dollars on illicit cannabis in 2022, highlighting a substantial unregulated market operating outside the medical and legal framework. This policy shift, if implemented, would transition cannabis from prohibition to a regulated system, potentially allowing clinicians to recommend cannabis products with known composition, quality assurance, and standardized dosing rather than advising patients toward black market sources of unknown potency and purity. Legalization would also enable clinical research and evidence generation within North Carolina, currently restricted under federal and state prohibition, to better understand cannabis efficacy and safety in patient populations. For physicians, this represents an opportunity to move from counseling patients to avoid cannabis entirely toward practicing evidence-based cannabis medicine with access to regulated products and established dosing guidelines. Clinicians in North Carolina should monitor the council’s recommendations as they advance through the legislative process, as legalization would substantially alter the clinical landscape for patient counseling and treatment options.
“We’re losing the opportunity to regulate product quality and guide our patients toward evidence-based dosing when they’re purchasing from uncontrolled sources, and that’s a clinical failure we should take seriously.”
💊 While North Carolina remains among states without legal cannabis access, the substantial illicit market documented in this report—estimated at $3.2 billion annually—suggests many patients are already self-medicating with unregulated products of unknown potency and purity. Healthcare providers in the state should recognize that patients may be obtaining cannabis through informal channels and should create nonjudgmental space to discuss use, as current legal prohibition does not prevent consumption but does prevent standardized dosing, quality assurance, or integration with conventional medical care. The gap between policy and practice is particularly relevant for patients with chronic pain, epilepsy, or other conditions where cannabis is being used in neighboring states, who may lack reliable information about product composition or drug interactions. As legalization discussions advance, clinicians should stay informed about potential policy changes while remaining aware that even if legalization occurs, the evidence base for cannabis in most clinical indications remains limited and heterogeneous. In the
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
FAQ
This News item was assembled from structured source metadata and pipeline scoring.
Have thoughts on this? Share it: